Administration of dimenhydrinate

ApprovedSmall molecule

Administration of dimenhydrinate is one of 7 small molecule programs targeting Peripheral Vertigo. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Peripheral VertigoActive, not recruiting

Peripheral VertigoApproved

Active, not recruiting

Competition

Competitive Landscape

8 competitors in Peripheral Vertigo

#DrugCompanyPhaseTrials

Ativan

BBausch Health Americas, Inc.

Piracetam

1 3

Valium

Akero Therapeutics

Phase 3

1 4

Administration of dimenhydrinate

KKocaeli University

Approved

1 5

Intranasal Drug

AAuris Medical AG

Phase 2

1 6

Benadryl

PParkedale

Preclinical

1 7

Alka-Seltzer

AAbbott

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Peripheral Vertigo1 trial

Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo

Completed·KKocaeli University·Phase 4·NCT01890538·94 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Administration of dimenhydrinate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Administration of dimenhydrinate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Administration of dimenhydrinate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Kocaeli University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: KKocaeli University

Administration of dimenhydrinate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Peripheral Vertigo1 trial

References

Drug Info

Quick Facts

Related News